ESMO 2026 (Madrid) — trial hub
ESMO Congress 2026, Madrid, 23–27 October. Telegraphic, single-topic summaries; numbers from the cited sources.
ESMO 2026 coverage
- New 7 Nov 2026: ESMO 2026 trial matching game — match 10 trials to disease or regimen
- New 6 Nov 2026: ESMO 2026 week update — what changed this week (2–6 November)
- ESMO 2026 Presidential Symposium I — INTerpath-001, VOLGA, DeLLphi-305, DASL-HiCaP
- ESMO 2026 Presidential Symposium II — Krascendo 1, SAFFRON, CLARITY-Gastric 01, HARMONi-GI1
- ESMO 2026 in NEJM — HEALER and OptiTROP-Lung06
- New: ESMO 2026 forest plot — hazard ratios for all 10 trials on one page
- ESMO 2026 trial quiz — 10 interactive questions
- Best of cancer media — curated threads, landmark papers, interviews, debates
Earlier conferences and trials
- ASCO GI 2026 — HERIZON-GEA-01, BREAKWATER, COMMIT
- DESTINY-Breast11 · FLAURA2 · DeFi (nirogacestat)
- FDA oncology approvals, October 2026
Trial briefs, October 2026 (from Dr. Senthil Kumar’s X threads)
- Atomic: Adjuvant Io In Colon Cancer
- Her2Climb-05: Maintenance Intensifies
- Esr1: Molecular Progression Before Scan Progression
- Nrg-Br002: Ablation Does Not Automatically Mean Better Survival
- Psmaddition: Radioligands Move Earlier
- Rampp: Cytoreductive Prostatectomy
- Nant: Chemotherapy-Free Neoadjuvant Ovarian Therapy?
- FRα ADCS: THE OVARIAN PIPELINE EXPANDS
- Excaliber-Rrmm: Big Pfs Signal, Real Toxicity
- Frail Myeloma & The “Cure” Question
- Bispecifics Move Earlier
- Added Update: First-Line Cll
- Added Update: Post-Io Rcc
- Added Updates: Lung & Biliary Cancer
- ctDNA MOVES FROM PROGNOSIS TO TREATMENT SELECTION
- Multicancer Screening: A Major Reality Check
- The Watch-List
- 🚀 Destiny-Breast11 — Adcs Enter Neoadjuvant Therapy
- ⚔️ NON-pCR: T-DM1 OR T-DXd?
- 🌍 First-Line Her2+ Metastatic Breast Cancer — 2026
- 💎 Her2+ Maintenance — Patina Vs Her2Climb-05
- ⚔️ Second-Line Her2+ Mbc — What After First-Line?
- 🧠 Her2+ Brain Metastases — A Different Sequencing Problem
- 🇮🇳 Her2 Breast Cancer — 2026 Clinical Rulebook